JP2021038228A5 - - Google Patents

Download PDF

Info

Publication number
JP2021038228A5
JP2021038228A5 JP2020180340A JP2020180340A JP2021038228A5 JP 2021038228 A5 JP2021038228 A5 JP 2021038228A5 JP 2020180340 A JP2020180340 A JP 2020180340A JP 2020180340 A JP2020180340 A JP 2020180340A JP 2021038228 A5 JP2021038228 A5 JP 2021038228A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
oxo
methyl
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020180340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021038228A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021038228A publication Critical patent/JP2021038228A/ja
Publication of JP2021038228A5 publication Critical patent/JP2021038228A5/ja
Priority to JP2022069599A priority Critical patent/JP2022109965A/ja
Withdrawn legal-status Critical Current

Links

JP2020180340A 2012-09-07 2020-10-28 聴覚喪失治療 Withdrawn JP2021038228A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022069599A JP2022109965A (ja) 2012-09-07 2022-04-20 聴覚喪失治療

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698475P 2012-09-07 2012-09-07
US61/698,475 2012-09-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019091552A Division JP2019172679A (ja) 2012-09-07 2019-05-14 聴覚喪失治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022069599A Division JP2022109965A (ja) 2012-09-07 2022-04-20 聴覚喪失治療

Publications (2)

Publication Number Publication Date
JP2021038228A JP2021038228A (ja) 2021-03-11
JP2021038228A5 true JP2021038228A5 (enExample) 2021-07-26

Family

ID=50237627

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015531223A Withdrawn JP2015527398A (ja) 2012-09-07 2013-09-06 聴覚喪失治療
JP2019091552A Withdrawn JP2019172679A (ja) 2012-09-07 2019-05-14 聴覚喪失治療
JP2020180340A Withdrawn JP2021038228A (ja) 2012-09-07 2020-10-28 聴覚喪失治療
JP2022069599A Pending JP2022109965A (ja) 2012-09-07 2022-04-20 聴覚喪失治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015531223A Withdrawn JP2015527398A (ja) 2012-09-07 2013-09-06 聴覚喪失治療
JP2019091552A Withdrawn JP2019172679A (ja) 2012-09-07 2019-05-14 聴覚喪失治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022069599A Pending JP2022109965A (ja) 2012-09-07 2022-04-20 聴覚喪失治療

Country Status (7)

Country Link
US (3) US20150209367A1 (enExample)
EP (2) EP3970725B1 (enExample)
JP (4) JP2015527398A (enExample)
AU (1) AU2013312358B2 (enExample)
CA (1) CA2883896C (enExample)
HK (1) HK1211875A1 (enExample)
WO (1) WO2014039781A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669693C (en) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
AU2013312358B2 (en) * 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
TWI625332B (zh) * 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕(notch)路徑傳訊抑制化合物
US20180326080A1 (en) * 2015-10-27 2018-11-15 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
RU2707284C1 (ru) * 2015-10-30 2019-11-26 Пайплайн Терапьютикс, Инк. Дибензоазепиновые соединения и их применение для лечения ушных заболеваний и нарушений
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
CN110248650A (zh) 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
KR20190098998A (ko) * 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
JP2022504265A (ja) 2018-10-02 2022-01-13 フリークエンシー セラピューティクス インコーポレイテッド 耳治療薬に関する医薬組成物及び方法
TW202103692A (zh) 2019-04-08 2021-02-01 美商頻率醫療公司 用於治療聽力損失之組合物及方法
TWI781536B (zh) 2021-02-26 2022-10-21 國立臺灣科技大學 藥物釋放組合物、其製造方法及其用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
USD309535S (en) 1987-03-30 1990-07-31 Chromcraft Furniture Corp. Chair
USD360535S (en) 1994-02-14 1995-07-25 Staffan Sjoberg Combined beach chair and beach mattress
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DK0951466T3 (da) 1996-12-23 2009-03-16 Elan Pharm Inc Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser
US6683048B1 (en) 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
AU4206200A (en) 1999-04-05 2000-10-23 Adherex Technologies Inc. Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation
ATE384704T1 (de) 1999-12-17 2008-02-15 Novartis Vaccines & Diagnostic Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
AU779875B2 (en) 2000-01-24 2005-02-17 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US7365196B2 (en) 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
USD447031S1 (en) 2000-04-20 2001-08-28 Wang Keaun Oh Hand carry air tacker
CA2412764C (en) 2000-07-11 2014-06-03 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
AU1074702A (en) 2000-11-02 2002-05-15 Merck Sharp & Dohme Sulfamides as gamma-secretase inhibitors
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US6483732B2 (en) 2000-12-13 2002-11-19 Koninklijke Philips Electronics N.V. Relational content addressable memory
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
EP1503998B1 (en) 2002-05-01 2009-07-01 MERCK SHARP & DOHME LTD. Heteroaryl substituted spirocyclic sufamides for inhibition of gamma secretase
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
CA2522176A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
CL2004000647A1 (es) 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
US20050019801A1 (en) 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
RU2383547C2 (ru) 2003-08-28 2010-03-10 Чоонгвае Фарма Корпорейшн Модуляция бета-катенин/tcf-активируемой транскрипции
EP1667984B1 (en) 2003-09-24 2011-05-18 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
CA2554403A1 (en) 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
WO2005072793A1 (en) 2004-01-29 2005-08-11 The Charles Stark Draper Laboratory, Inc. Implantable drug delivery apparatus
ES2375627T3 (es) 2004-02-23 2012-03-02 Eli Lilly And Company Anticuerpos anti-abeta.
JP2006117536A (ja) * 2004-10-19 2006-05-11 Kyoto Univ 内耳の有毛細胞を誘導するための医薬
WO2007030743A2 (en) 2005-09-08 2007-03-15 Massachusetts Eye & Ear Infirmary Cochlear implants containing biological cells and uses thereof
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
WO2007121272A2 (en) * 2006-04-11 2007-10-25 The Board Of Regents Of The University Of Texas System Methods and compositions involving nucleotide repeat disorders
US8175269B2 (en) 2006-07-05 2012-05-08 Oracle International Corporation System and method for enterprise security including symmetric key protection
CA2669693C (en) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CA2694209C (en) 2007-08-14 2013-09-17 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CA2710913A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
GB2461186B (en) 2008-04-21 2010-09-01 Otonomy Inc Controlled release corticosteroid compositions and methods for the treatment of otic disorders
BRPI0912482A2 (pt) 2008-05-14 2020-08-18 Otonomy, Inc composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CA2743436C (en) * 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2375895A4 (en) 2008-12-11 2012-05-30 Merck Sharp & Dohme METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
US8609897B2 (en) 2009-02-06 2013-12-17 Merck Sharp & Dohme Corp. Trifluoromethylsulfonamide gamma secretase inhibitor
AU2010311035B2 (en) 2009-10-28 2013-05-16 Pfizer Inc. Imidazole derivatives as casein kinase inhibitors
CA134865S (en) 2010-02-11 2010-11-10 Hankook Tire Co Ltd Automobile tire
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
CN102947451B (zh) 2010-05-26 2017-09-22 库尔纳公司 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
RU2456356C1 (ru) 2011-04-29 2012-07-20 Борис Сергеевич Кустов Коллоидный раствор наносеребра и способ его получения
AU2013312358B2 (en) * 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
AU2013312305B2 (en) 2012-09-07 2018-06-28 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
CA2905842C (en) 2013-03-14 2023-02-21 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
WO2015168149A2 (en) 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
TWI625332B (zh) 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕(notch)路徑傳訊抑制化合物
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
WO2020112883A1 (en) 2018-11-30 2020-06-04 Massachusetts Eye And Ear Infirmary Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells

Similar Documents

Publication Publication Date Title
JP2021038228A5 (enExample)
JP2019172679A5 (enExample)
JPH08510479A (ja) 眼の炎症障害を処置するための3‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物
JP6720301B2 (ja) 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をin vivoで増強する方法
JP2022109965A (ja) 聴覚喪失治療
JPH11512438A (ja) 末梢性活性抗痛覚過敏オピエート
JP2019503386A5 (enExample)
JP2013516488A (ja) 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療
JP7132277B2 (ja) スミス‐マゲニス症候群を治療するためのタシメルテオン
JP2004518653A (ja) 不安障害を治療する方法
JP2002520277A (ja) 不眠症を治療する方法
BRPI0609915A2 (pt) métodos para tratar aterosclerose
JP2012526832A (ja) トランスノルセルトラリン及びセロトニン受容体1a作動剤/拮抗剤を含む組成物及びその使用
HUP0100998A2 (hu) (2E)-5-amino-5-metil-hex-2-én-sav-N-metil-N-{(1R)-1-[N-metil-N-/(1R)-1-(metil-karbamoil)-2-fenil-etil/-karbamoil]-2-(2-naftil)-etil}-amid-sók, eljárás azok előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
US20250144116A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
JP2009514961A (ja) アンギオテンシンii受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ
CN116887823A (zh) 用于外用施用加巴喷丁类药物的方法和制剂
JP2005500400A5 (enExample)
US6462089B1 (en) Method for correcting the vigilance disorders associated with myopathies
US20250170114A1 (en) Methods of treatment using t-type calcium channel modulators
EP2004167A1 (en) Renin inhibitors for the treatment of hypertension
US20240358668A1 (en) Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate
WO2019071272A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD)
US8957098B2 (en) Use of leflunomide and malononitrilamides
EP3743059B1 (fr) Dérivés aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prévention et le traitement des douleurs relatives au nerf trijumeau